Early nitazoxanide therapy significantly reduces viral load in Covid-19: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-10-27 13:26 GMT | Update On 2020-10-28 07:19 GMT

Brazil: Early nitazoxanide therapy is safe and helps in a significant reduction of viral load in patients with mild Covid-19, suggests a recent study in medRxiv. However, it did not help in symptom resolution compared to placebo after 5 days of therapy.

The antiparasitic drug nitazoxanide is available widely and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection. The multicenter, randomized, double-blind, placebo-controlled trial by Patricia R. M. Rocco, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, and colleagues enrolled adult patients who presented up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue)

Patients were randomized in the ratio 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days.

The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, general laboratory tests, serum biomarkers of inflammation, and hospitalization rate. Adverse events were also assessed. From June 8 to August 20, 2020, 1,575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analyzed.

Key findings of the study include:

Median time from symptom onset to first dose of study drug was 5 (4-5) days.
At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms.
At the 1-week follow-up, 78% in the nitazoxanide arm and 57% in the placebo arm reported complete resolution of symptoms.
Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm.
Viral load was also reduced after nitazoxanide compared to placebo.
No serious adverse events were observed.

"In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly," concluded the authors.

"Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial," is published in medRxiv.

DOI: https://www.medrxiv.org/content/10.1101/2020.10.21.20217208v1

Article Source : journal medRxiv

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Early nitazoxanide therapy significantly reduces viral load in Covid-19: Study

Similar News

15 Percent of COPD Exacerbation Patients Develop Arrhythmias, Tripling In-Hospital Death Risk: Meta-Analysis

Mouth Breathing Linked to Sleep-Disordered Breathing in Children, finds study

Minimal-Equipment Pulmonary Rehab Matches Benefits of Full Gym Setup: JAMA

Even healthy children can be severely affected by RSV, reveals research

Breathing device could have profound impact on survival for people with sleep apnoea and type 2 diabetes

Low BMI Raises Risk of TB in IGRA-Positive Contacts, suggests research

Surgery to treat chronic sinus disease more effective than antibiotics, finds study

CPAP Therapy Eases Acid Reflux Symptoms in Patients With Sleep Apnea, Indian Study Reports